Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic P_MMSCs and UC-MMSCs
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Assessment of the clinical effects of infusions of cryopreserved allogeneic multipotent
mesenchymal stem cells of the placenta and umbilical cord for COVID-19 patients with acute
respiratory distress syndrome.